Axsome Therapeutics (AXSM) vs Praxis Precision Medicines (PRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 385.4% versus a gain of 43.3%. Over five years, AXSM leads with a +324.1% price change compared with -12.2% for PRAX. Axsome Therapeutics is the larger company by market cap ($8.85 billion vs $7.34 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | PRAX |
|---|---|---|
| Share price | $169.03 | $263.02 |
| Market cap | $8.85B | $7.34B |
| 1-day change | -0.62% | -0.20% |
| YTD return | -6.88% | -10.58% |
| 1-year return | +43.27% | +385.45% |
| 5-year return | +324.14% | -12.19% |
| Forward P/E | 35.94 | — |
| EPS (TTM) | $-3.74 | $-12.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $0 |
| Revenue growth (YoY) | +65.55% | -100.00% |
| Net income (latest FY) | $-183.17M | $-303.27M |
| Gross margin | 92.56% | — |
| Operating margin | -26.12% | — |
| Net margin | -28.69% | — |
| 52-week high | $260.19 | $392.70 |
| 52-week low | $119.20 | $50.56 |
| Distance from 52-week high | -35.04% | -33.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +68.40% | +145.01% |
| Average volume | 712.30K | 408.88K |
| Shares outstanding | 52.38M | 27.92M |
| Employees | 1,346 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed AXSM by 342.2 percentage points over the past year.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs -100.00%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
AXSM vs PRAX FAQ
Which is bigger, Axsome Therapeutics or Praxis Precision Medicines?
Axsome Therapeutics (AXSM) is larger, with a market capitalization of $8.85B compared with $7.34B for Praxis Precision Medicines (PRAX).
Which stock has performed better over the past year, AXSM or PRAX?
PRAX returned +385.45% over the past 12 months, compared with +43.27% for AXSM (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Praxis Precision Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.